This is part of a post I made on a BB at SI regarding GNBT...
One thing I teach my students is to do research and I tried to apply the same principles to that article on GNBT today. First of all, does the guy really even know what he's talking about? With the brief study of his biography, this really isn't even his field.
============
Adam Feuerstein
TheStreet.com Senior ColumnistRealMoney
RSS Feed Email This Author
Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
====================
His focus is on the oral insulin and there is much more to GNBT than that. He totally disregards the income potential of CVS selling GNBT's diet aide. He seems to think we should take his opinion that, "Generex is a total bust." Do you really think the co-founder of AMGN would endanger his life's reputation with the reports that he put out on GNBT a few months ago stating the direction of the company? I think he has much more credibility than Adam with his political science degree.
Next, it looks like most of the articles Adam writes are negative about these stocks we trade. My first thought was I wonder if his friends and relatives are benefiting from these calls he makes trashing stocks. In addition, the person who taught me to trade kept telling me, "Shut out the noise." He meant to do my own DD and read the chart while not listening to everyone else. In short, I still believe in the company and while Adam might have affected the stock in the short-term, it'll do fine as the good news continues IMHO.
Lexi
